A control study of duloxetine and sertraline in the treatment of patients with depression

Abstract

Abstract: AIM: To study the efficacy and safety of duloxetine in the treatment of patients with depression.METHODS: In this 6-week randomized control trial, patients meeting CCMD-3 criteria for depressive episode were randomizedly divided to duloxetine group (60 mg/d, n =48) and sertraline group (50 -150 mg/d, n =50).Clinic effectiveness was evaluated using HAMD, adverse reactions and safety were assessed with TESS and laboratory examination.RESULTS: The remission rate and response rate were 39.6 % and 68.8 % for duloxetine group and 30.0 % and 58.0 % for sertraline group respectively, without statistically significant difference between two groups.But duloxetine- treated patients showed significantly greater improvement in the HAMD total score at week 1, 2, 4 respectively.The main adverse reactions were lack of appetite, dry mouth, sweating, constipation, nausea and vomit.The dropped out rates were 6.3 % for duloxetine group and 8.0 % for sertraline group respectively, without statistically significant difference between two groups.CONCLUSION: Duloxetine appeared to be a safe and effective treatment for depression.

Key words: duloxetine, sertraline, safety, efficacy/tolerability, depression

CLC Number:

R749.4

SHEN Xin-hua, QIAN Min-cai, LIN Min, FEI Xiao-cong, WAN Shi-liang. A control study of duloxetine and sertraline in the treatment of patients with depression[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(2): 207-209.

References

[1] Kessler RC, ChiuWT, Demler O, et al.Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication[J].Arch Gen Psychiatry, 2005, 62(6):617-627.
[2] Rush AJ, Fava M, Wisniewski SR, et al.Sequenced treatment alternatives to relieve depression (STAR＊D): rationale and design[J].Control Clin Trials, 2004, 25 (1):119-142.
[3] Detke MJ, Lu Y, Goldstein DJ, et al.Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression[J].J Psychiatr Res, 2002, 36(6):383-390.
[4] Detke MJ, Lu Y, Goldstein DJ, et al.Duloxetine, 60 mg once daily, for major depressive disorder:a randomized double-blind placebo-controlled trial[J].J Clin Psychiatry, 2002, 63(4):308-315.
[5] Goldstein DJ, Mallinckrodt C, Lu Y, et al.Duloxetine in the treatment of major depressive disorder:a double-blind clinical trial[J].J Clin Psychiatry, 2002, 63(3):225-231.
[6] Lee P, Shu L, Xu X, et al.Once-daily duloxetine 60 mg in the treatment of major depressive disorder:multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil[J]. Psychiatry Clin Neurosci, 2007, 61(3):295-307.
[7] Perahib DG, Pritchett YL, Kajdasz DK, et al.A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder[J].J Psychiatr Res, 2008, 42(1):22-34.
[8] Mallinckrodt CH, Parkash A, Houston JP, et al.Differential antidepressant symptom efficacy:placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram) [J].Neuropsychobioiogy, 2007, 56(2/3):73-85.
[9] Klan A, Bose A, Alexopoulos GS, et al.Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder[J].Clin Drug Investig, 2007, 27(7):481-492.
[10] Perahia DG, Kajdase DK, Walker DJ, et al.Duloxetine 60 mg once daily in the treatment of milder major depressive disorder[J].Int J Clin Pract, 2006, 60(5):613-620.
[11] Perahia DG,Wang F, Mallinckrodt CH, et al.Duloxetine in the treatment of major depressive disorder:a placeboand paroxetine-controlled trial[J].Eur Psychiatry, 2006, 21(6):367-378.
[12] Hudson JI, Perahia DG, Gilaberte I, et al.Duloxetine in the treatment of major depressive disorder:an open-lable study[J].BMC Psychiatry, 2007, 7:43.

[1]	XIAO Yue, LI Tangfei, XUE Qianfu. Analysis of the efficacy and safety of Peg-IFN-α in the treatment of essential thrombocythemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1049-1055.
[2]	ZHANG Taotao, SU Wenxiu, TIAN Limin. Research progress on the relationship between subclinical hypothyroidism and depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 954-960.
[3]	JIA Boying, ZHOU Shuang, WAN Liyan, ZHOU Ying, CUI Yimin. Drug-induced dysphagia risk in elder people——A pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) database [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1109-1120.
[4]	LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HUANG Kai. Safety analysis on bioequivalence studies of orally inhaled drug products in healthy Chinese subjects#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1131-1138.
[5]	LIANG Meifang, CHEN Qingzhuang, YANG Peiqun, WANG Yong. Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: A real-world study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 785-792.
[6]	HE Teng, XU Xiangyang, XU Xiangqing, LIU Cunming, YANG Chun. Ketamine for depression treatment: past, present, and future [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1125-1132.
[7]	BAO Jing, CHEN Xiaowen, XIA Liang, ZHAO Yuchen, XIA Ruixiang, XIA Hailong. Clinical efficacy and safety of ixazomib in the treatment of multiple myeloma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 782-786.
[8]	WANG Yeqing, WANG Yuhong, LIU Jian, ZHAO Hongqing, ZOU Manshu. Research progress of relevance between cholecystokinin and depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 672-679.
[9]	CHEN Ying, YUAN Yonggui. Research progress in the treatment of depression with monome of Chinese herb, drug pairs, compound prescriptions and Chinese patent drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 586-593.
[10]	YANG Shitao, ZHU Yihong, TANG Wenxin. Effects of aripiprazole combined with duloxetine on the treatment effect and VEGF level in patients with refractory depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 937-942.
[11]	GE Wei, SHENG Wenyan, XU Qibing, LI Qiushi, SU Lingya, WU Shuangqing. Effects of SSRI antidepressant sertraline on ocular surface function in patients with postpartum depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 440-446.
[12]	FENG Rui, ZHANG Jiali, HE Mingchao, LI Yue, ZHANG Yan. Pharmacological targets and clinical application of traditional Chinese medicine and active components in the prevention and treatment for depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 467-474.
[13]	PAN Luping, SHI Wujie, SHEN Zhipeng. Efficacy and safety of etoposide combined with carboplatin in children with recurrent medulloblastoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 189-195.
[14]	SHI Lili, LIU Xingan, SHAN Guoyong. Efficacy and safety of apatinib in the further line treatment for patients with advanced colorectal cancer failed after standard therapy and the preliminary analysis of efficacy predictors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1388-1394.
[15]	YANG Haijing, YU Jicheng, WANG Jingjing, LI Nanyang, WU Jufang, ZHANG Hai, XUE Tao, DAI Weiguo, DING Tianling, CAO Guoying. Risk management of biological agents in phase I clinical trials: Case sharing [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 44-48.